Skip to main content
  • ASM
    • Antimicrobial Agents and Chemotherapy
    • Applied and Environmental Microbiology
    • Clinical Microbiology Reviews
    • Clinical and Vaccine Immunology
    • EcoSal Plus
    • Eukaryotic Cell
    • Infection and Immunity
    • Journal of Bacteriology
    • Journal of Clinical Microbiology
    • Journal of Microbiology & Biology Education
    • Journal of Virology
    • mBio
    • Microbiology and Molecular Biology Reviews
    • Microbiology Resource Announcements
    • Microbiology Spectrum
    • Molecular and Cellular Biology
    • mSphere
    • mSystems
  • Log in
  • My alerts
  • My Cart

Main menu

  • Home
  • Articles
    • Current Issue
    • Accepted Manuscripts
    • Archive
    • Minireviews
  • For Authors
    • Submit a Manuscript
    • Scope
    • Editorial Policy
    • Submission, Review, & Publication Processes
    • Organization and Format
    • Errata, Author Corrections, Retractions
    • Illustrations and Tables
    • Nomenclature
    • Abbreviations and Conventions
    • Publication Fees
    • Ethics Resources and Policies
  • About the Journal
    • About AAC
    • Editor in Chief
    • Editorial Board
    • For Reviewers
    • For the Media
    • For Librarians
    • For Advertisers
    • Alerts
    • RSS
    • FAQ
  • Subscribe
    • Members
    • Institutions
  • ASM
    • Antimicrobial Agents and Chemotherapy
    • Applied and Environmental Microbiology
    • Clinical Microbiology Reviews
    • Clinical and Vaccine Immunology
    • EcoSal Plus
    • Eukaryotic Cell
    • Infection and Immunity
    • Journal of Bacteriology
    • Journal of Clinical Microbiology
    • Journal of Microbiology & Biology Education
    • Journal of Virology
    • mBio
    • Microbiology and Molecular Biology Reviews
    • Microbiology Resource Announcements
    • Microbiology Spectrum
    • Molecular and Cellular Biology
    • mSphere
    • mSystems

User menu

  • Log in
  • My alerts
  • My Cart

Search

  • Advanced search
Antimicrobial Agents and Chemotherapy
publisher-logosite-logo

Advanced Search

  • Home
  • Articles
    • Current Issue
    • Accepted Manuscripts
    • Archive
    • Minireviews
  • For Authors
    • Submit a Manuscript
    • Scope
    • Editorial Policy
    • Submission, Review, & Publication Processes
    • Organization and Format
    • Errata, Author Corrections, Retractions
    • Illustrations and Tables
    • Nomenclature
    • Abbreviations and Conventions
    • Publication Fees
    • Ethics Resources and Policies
  • About the Journal
    • About AAC
    • Editor in Chief
    • Editorial Board
    • For Reviewers
    • For the Media
    • For Librarians
    • For Advertisers
    • Alerts
    • RSS
    • FAQ
  • Subscribe
    • Members
    • Institutions
Mechanisms of Resistance

High Prevalence of the ermB Gene among Erythromycin-Resistant Streptococcus pneumoniae Isolates in Germany during the Winter of 2000-2001 and In Vitro Activity of Telithromycin

Michael Kresken, Beate Henrichfreise, Simone Bagel, Johannes Brauers, Bernd Wiedemann
Michael Kresken
Antiinfectives Intelligence GmbH, 53121 Bonn
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • For correspondence: michael.kresken@antiinfectives-intelligence.de
Beate Henrichfreise
Antiinfectives Intelligence GmbH, 53121 BonnPharmazeutische Mikrobiologie, Rheinische-Friedrich-Wilhelms-Universität, 53115 Bonn, Germany
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Simone Bagel
Antiinfectives Intelligence GmbH, 53121 Bonn
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Johannes Brauers
Antiinfectives Intelligence GmbH, 53121 Bonn
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Bernd Wiedemann
Antiinfectives Intelligence GmbH, 53121 BonnPharmazeutische Mikrobiologie, Rheinische-Friedrich-Wilhelms-Universität, 53115 Bonn, Germany
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
DOI: 10.1128/AAC.48.8.3193-3195.2004
  • Article
  • Figures & Data
  • Info & Metrics
  • PDF
Loading

ABSTRACT

Of 595 isolates of Streptococcus pneumoniae from outpatients with respiratory tract infections, collected from 17 microbiology laboratories, 14.1% were resistant to erythromycin. Eighty-three erythromycin-resistant isolates were genetically analyzed, 83.1% of which harbored the ermB gene. Only four isolates (4.8%) harbored the mefA gene. Telithromycin exhibited potent activity against all isolates.

The two most common mechanisms of macrolide resistance among Streptococcus pneumoniae isolates are efflux of the drug mediated by a transport protein encoded by the mefA (subclass mefE) gene and target-site modification due to a methylase encoded by the ermB gene (subclass ermAM) (15, 20). Isolates harboring the mefA gene display low-level resistance to 14- and 15-membered-ring macrolides, whereas isolates with the ermB genotype display high-level resistance to all macrolides, lincosamides, and group B streptogramins (2, 6, 15).

Telithromycin, the first compound of the ketolide class, is highly active against pneumococcal isolates, including both ermB- and mefA-mediated macrolide-resistant isolates (4, 7, 13, 17).

(This study was presented in part at the 42nd Interscience Conference on Antimicrobial Agents and Chemotherapy, 27 to 30 September 2002, San Diego, Calif.)

A total of 595 S. pneumoniae isolates from outpatients with respiratory tract infections were collected from 17 medical microbiology laboratories throughout Germany during two surveillance studies conducted between October 2000 and April 2001. The inclusion of only one isolate per patient was permitted. Susceptibility testing was performed by broth microdilution with reference to the guidelines of the National Committee of Clinical Laboratory Standards (9). Broth microdilution plates were purchased from Merlin GmbH, Bornheim, Germany. The antibacterial agents tested were erythromycin, clindamycin, telithromycin, penicillin, tetracycline, and trimethoprim-sulfamethoxazole (1:19 ratio). NCCLS breakpoints were applied to categorize susceptibility patterns (10). Erythromycin-resistant isolates were tested for the presence of the ermB or mefA gene using a duplex PCR (18). Pulsed-field gel electrophoresis (PFGE) was used to determine clonal relationships between erythromycin-resistant isolates (16).

Of the 595 isolates, 84 (14.1%) and 76 (12.8%) were resistant to erythromycin and clindamycin, respectively. Seventy-six (90.5%) and 34 (40.5%) out of the 84 erythromycin-resistant isolates were resistant to tetracycline and intermediate (n = 3) or resistant (n = 31) to trimethoprim-sulfamethoxazole, respectively. In addition, 18 (21.4%) of the 84 erythromycin-resistant isolates were nonsusceptible to penicillin, though none were penicillin resistant (MIC, ≥2 mg/liter). All erythromycin-resistant isolates were highly susceptible to telithromycin (MICs of ≤0.06 [n = 83] and 0.125 [n = 1] mg/liter).

Eighty-three out of the 84 erythromycin-resistant isolates were available for duplex PCR and PFGE. Sixty-nine (83.1%) and four (4.8%) isolates were positive for the ermB and mefA genes, respectively. None of the isolates harbored both resistance genes. Ten (12.0%) isolates hybridized neither with the ermB probe nor with the mefA probe. PFGE analysis revealed 17 different clones. Three clones (I to III) comprising a total of 66 (79.5%) isolates were predominant. Isolates of all three clones showed the ermB genotype and were resistant to both erythromycin and clindamycin. Clone I isolates were additionally resistant to tetracycline only, whereas clone II isolates showed also resistance to tetracycline and trimethoprim-sulfamethoxazole (one isolate tested intermediate to trimethoprim-sulfamethoxazole). Isolates of clone III were additionally resistant to tetracycline and trimethoprim-sulfamethoxazole and intermediate to penicillin (Table 1).

Erythromycin resistance varied markedly between the centers; the local resistance rate ranged from 0% to 45%. Isolates of clone I were detected in two centers located in western (Essen) and southern (Stuttgart) Germany, whereas those of clone II were detected in one center of southern Germany (Rosenheim) and in two centers of eastern Germany (Rostock and Görlitz), and those of clone III were found in three centers of eastern Germany (Greifswald, Görlitz, Rostock) (Fig. 1).

The rate of erythromycin resistance (14.1%) found in the present study confirms the findings of two other recently conducted studies in Germany. Reinert et al. reported erythromycin resistance to be present in 17.4% of 333 S. pneumoniae isolates collected from pediatric outpatients with respiratory tract infections (13). Of the 325 pneumococci isolated in the 1999-2000 PROTEKT surveillance study in Germany, 15.7% were erythromycin resistant (5). However, in the present study, 12.8% of all isolates were resistant to clindamycin, compared to 8.7% reported by Reinert et al. (13).

In our study, >80% of the erythromycin-resistant isolates harbored the ermB gene, and <5% harbored the mefA gene. In previous studies from Germany, rates for ermB were in the range of 40.8 to 74.0%, and those for mefA were in the range of 20.5 to 51.0% (3, 11-13). ermB/mefA ratios of >80% have been reported from various other European countries, such as Belgium, France, Italy, and Spain, whereas mefA-mediated efflux was found to be the predominant mechanism in isolates in the United States and Canada (3).

Ten isolates of our series with a macrolide resistance phenotype were negative for the ermB and mefA genes. Other mechanisms found to confer macrolide resistance in pneumococci are mutations in the 23S rRNA or alterations in the ribosomal proteins L4 and L22 and a methylase encoded by the ermA (subclass ermTR) gene (3, 4, 14, 19).

The high rate of occurrence of ermB in our study was related to the dissemination of three clones. Resistance to other classes of antibacterial agents was widespread among these isolates. This was especially true for resistance to tetracycline. We did not look for the underlying mechanism of tetracycline resistance, but the association of erythromycin resistance and tetracycline resistance may be due to the conjugative transposon Tn1545, which encodes erythromycin resistance via the ermB gene and tetracycline resistance via the tetM gene (1). In our study, 23.2% of ermB-positive isolates were intermediate to penicillin. This figure corresponds to the rate of 19.5% reported by Reinert et al. in a previous study in Germany (12).

In vitro macrolide resistance in S. pneumoniae infections due to both the efflux and the methylase mechanisms has been demonstrated to result in clinical failure (8). Telithromycin appears to be an alternative to macrolides for the treatment of community-acquired respiratory tract infections, especially in areas with a high prevalence of macrolide-resistant pneumococci.

FIG. 1.
  • Open in new tab
  • Download powerpoint
FIG. 1.

Spread of three erythromycin-resistant S. pneumoniae clones with the ermB genotype in Germany.

View this table:
  • View inline
  • View popup
TABLE 1.

Erythromycin-resistant clones of S. pneumoniae identified by PFGE

ACKNOWLEDGMENTS

This work was supported in part by Aventis Pharma Germany.

We are grateful to Gabriele Bierbaum and Hans-Georg Sahl for giving us the opportunity to perform PFGE in their laboratory. We also thank Monika Pinkwart and Andrea Reipert for their support with PFGE.

FOOTNOTES

    • Received 20 November 2003.
    • Returned for modification 1 March 2004.
    • Accepted 3 April 2004.
  • American Society for Microbiology

REFERENCES

  1. ↵
    Courvalin, P., and C. Carlier. 1987. Tn1545: a conjugative shuttle transposon. Mol. Gen. Genet. 206:259-264.
    OpenUrlCrossRefPubMedWeb of Science
  2. ↵
    Descheemaeker, P., S. Chapelle, C. Lammens, M. Hauchecorne, M. Wijdooghe, P. Vandamme, M. Ieven, and H. Goossens. 2000. Macrolide resistance and erythromycin resistance determinants among Belgian Streptococcus pyogenes and Streptococcus pneumoniae isolates. J. Antimicrob. Chemother. 45:167-173.
    OpenUrlCrossRefPubMedWeb of Science
  3. ↵
    Farrell, D. J., I. Morrissey, S. Bakker, and D. Felmingham. 2002. Molecular characterization of macrolide resistance mechanisms among Streptococcus pneumoniae and Streptococcus pyogenes isolated from the PROTEKT 1999-2000 study. J. Antimicrob. Chemother. 50(Suppl. S1):39-47.
    OpenUrlCrossRefPubMedWeb of Science
  4. ↵
    Farrell, D. J., S. Douthwaite, I. Morrissey, S. Bakker, J. Poehlsgaard, L. Jakobsen, and D. Felmingham. 2003. Macrolide resistance by ribosomal mutation in clinical isolates of Streptococcus pneumoniae from the PROTEKT 1999-2000 study. Antimicrob. Agents Chemother. 47:1777-1783.
    OpenUrlAbstract/FREE Full Text
  5. ↵
    Felmingham, D. 2001. Microbiological profile of telithromycin, the first ketolide antimicrobial. Clin. Microbiol. Infect. 7(Suppl. 3):2-10.
    OpenUrl
  6. ↵
    Felmingham, D., R. R. Reinert, Y. Hirakata, and A. Rodloff. 2002. Increasing prevalence of antimicrobial resistance among isolates of Streptococcus pneumoniae from the PROTEKT surveillance study, and competitive in vitro activity of the ketolide, telithromycin. J. Antimicrob. Chemother. 50:25-37.
    OpenUrlCrossRefPubMedWeb of Science
  7. ↵
    Hoban, D. J., A. K. Wierzbowski, K. Nichol, and G. G. Zhanel. 2001. Macrolide-resistant Streptococcus pneumoniae in Canada during 1998-1999: prevalence of mef(A) and erm(B) and susceptibilities to ketolides. Antimicrob. Agents Chemother. 45:2147-2150.
    OpenUrlAbstract/FREE Full Text
  8. ↵
    Lonks, J. R., J. Garau, L. Gomez, M. Xercavins, A. Ochoa de Echaguen, I. F. Gareen, P. T. Reiss, and A. A. Medeiros. 2002. Failure of macrolide antibiotic treatment in patients with bacteremia due to erythromycin-resistant Streptococcus pneumoniae. Clin. Infect. Dis. 35:556-564.
    OpenUrlCrossRefPubMedWeb of Science
  9. ↵
    National Committee for Clinical Laboratory Standards. 2000. Methods for dilution antimicrobial susceptibility tests. Approved standard M7-A5, 5th ed. National Committee for Clinical Laboratory Standards, Wayne, Pa.
  10. ↵
    National Committee for Clinical Laboratory Standards. 2003. MIC testing supplemental tables M100-S13 (M7). National Committee for Clinical Laboratory Standards, Wayne, Pa.
  11. ↵
    Reinert, R. R., S. Simic, A. Al-Lahham, S. Reinert, M. Lemperle, and R. Lütticken. 2001. Antimicrobial resistance of Streptococcus pneumoniae recovered from outpatients with respiratory tract infections in Germany from 1998 to 1999: results of a national surveillance study. J. Clin. Microbiol. 39:1187-1189.
    OpenUrlAbstract/FREE Full Text
  12. ↵
    Reinert, R. R., A. Al-Lahham, M. Lemperle, C. Tenholte, C. Briefs, S. Haupts, H. H. Gerards, and R. Lütticken. 2002. Emergence of macrolide and penicillin resistance among invasive pneumococcal isolates in Germany. J. Antimicrob. Chemother. 49:61-68.
    OpenUrlCrossRefPubMedWeb of Science
  13. ↵
    Reinert, R. R., R. Lütticken, A. Bryskier, and A. Al-Lahham. 2003. Macrolide-resistant Streptococcus pneumoniae and Streptococcus pyogenes in the pediatric population in Germany during 2000-2001. Antimicrob. Agents Chemother. 47:489-493.
    OpenUrlAbstract/FREE Full Text
  14. ↵
    Reinert, R. R., A. Wild, P. Appelbaum, R. Lütticken, M. Y. Cil, and A. Al-Lahham. 2003. Ribosomal mutations conferring resistance to macrolides in Streptococcus pneumoniae clinical strains isolated in Germany. Antimicrob. Agents Chemother. 47:2319-2322.
    OpenUrlAbstract/FREE Full Text
  15. ↵
    Roberts, M. C., J. Sutcliffe, P. Courvalin, L. B. Jensen, R. Rood, and H. Seppälä. 1999. Nomenclature for macrolide and macrolide-lincosamide-streptogramin B resistance determinants. Antimicrob. Agents Chemother. 43:2823-2830.
    OpenUrlFREE Full Text
  16. ↵
    Sá-Leão, R., A. Tomasz, I. S. Sanches, A. Brito-Avô, S. E. Vilhelmsson, K. G. Kristinsson, and H. de Lencastre. 2000. Carriage of internationally spread clones of Streptococcus pneumoniae with unusual drug resistance patterns in children attending day care centers in Lisbon, Portugal. J. Infect. Dis. 182:1153-1160.
    OpenUrlCrossRefPubMedWeb of Science
  17. ↵
    Shortridge, V. D., P. Zhong, Z. Cao, J. M. Beyer, L. S. Almer, N. C. Ramer, S. Z. Doktor, and R. K. Flamm. 2002. Comparison of in vitro activities of ABT-773 and telithromycin against macrolide-susceptible and -resistant streptococci and staphylococci. Antimicrob. Agents Chemother. 46:783-786.
    OpenUrlAbstract/FREE Full Text
  18. ↵
    Sutcliffe, J., T. Grebe, A. Tait-Kamradt, and L. Wondrack. 1996. Detection of erythromycin-resistant determinants by PCR. Antimicrob. Agents Chemother. 40:2562-2566.
    OpenUrlAbstract/FREE Full Text
  19. ↵
    Syrogiannopoulos, G. A., I. N. Grivea, A. Tait-Kamradt, G. D. Katopodis, N. G. Beratis, J. Sutcliffe, P. C. Appelbaum, and T. A. Davies. 2001. Identification of an erm(A) erythromycin resistance methylase gene in Streptococcus pneumoniae isolated in Greece. Antimicrob. Agents Chemother. 45:342-344.
    OpenUrlAbstract/FREE Full Text
  20. ↵
    Tait-Kamradt, A., J. Clancy, M. Cronan, F. Dib-Hajj, L. Wondrack, W. Yuan, and J. Sutcliffe. 1997. mefE is necessary for the erythromycin-resistant M phenotype in Streptococcus pneumoniae. Antimicrob. Agents Chemother. 41:2251-2255.
    OpenUrlAbstract/FREE Full Text
View Abstract
PreviousNext
Back to top
Download PDF
Citation Tools
High Prevalence of the ermB Gene among Erythromycin-Resistant Streptococcus pneumoniae Isolates in Germany during the Winter of 2000-2001 and In Vitro Activity of Telithromycin
Michael Kresken, Beate Henrichfreise, Simone Bagel, Johannes Brauers, Bernd Wiedemann
Antimicrobial Agents and Chemotherapy Jul 2004, 48 (8) 3193-3195; DOI: 10.1128/AAC.48.8.3193-3195.2004

Citation Manager Formats

  • BibTeX
  • Bookends
  • EasyBib
  • EndNote (tagged)
  • EndNote 8 (xml)
  • Medlars
  • Mendeley
  • Papers
  • RefWorks Tagged
  • Ref Manager
  • RIS
  • Zotero
Print

Alerts
Sign In to Email Alerts with your Email Address
Email

Thank you for sharing this Antimicrobial Agents and Chemotherapy article.

NOTE: We request your email address only to inform the recipient that it was you who recommended this article, and that it is not junk mail. We do not retain these email addresses.

Enter multiple addresses on separate lines or separate them with commas.
High Prevalence of the ermB Gene among Erythromycin-Resistant Streptococcus pneumoniae Isolates in Germany during the Winter of 2000-2001 and In Vitro Activity of Telithromycin
(Your Name) has forwarded a page to you from Antimicrobial Agents and Chemotherapy
(Your Name) thought you would be interested in this article in Antimicrobial Agents and Chemotherapy.
Share
High Prevalence of the ermB Gene among Erythromycin-Resistant Streptococcus pneumoniae Isolates in Germany during the Winter of 2000-2001 and In Vitro Activity of Telithromycin
Michael Kresken, Beate Henrichfreise, Simone Bagel, Johannes Brauers, Bernd Wiedemann
Antimicrobial Agents and Chemotherapy Jul 2004, 48 (8) 3193-3195; DOI: 10.1128/AAC.48.8.3193-3195.2004
del.icio.us logo Digg logo Reddit logo Twitter logo CiteULike logo Facebook logo Google logo Mendeley logo
  • Top
  • Article
    • ABSTRACT
    • ACKNOWLEDGMENTS
    • FOOTNOTES
    • REFERENCES
  • Figures & Data
  • Info & Metrics
  • PDF

Related Articles

Cited By...

About

  • About AAC
  • Editor in Chief
  • Editorial Board
  • Policies
  • For Reviewers
  • For the Media
  • For Librarians
  • For Advertisers
  • Alerts
  • RSS
  • FAQ
  • Permissions
  • Journal Announcements

Authors

  • ASM Author Center
  • Submit a Manuscript
  • Article Types
  • Ethics
  • Contact Us

Follow #AACJournal

@ASMicrobiology

       

ASM Journals

ASM journals are the most prominent publications in the field, delivering up-to-date and authoritative coverage of both basic and clinical microbiology.

About ASM | Contact Us | Press Room

 

ASM is a member of

Scientific Society Publisher Alliance

Copyright © 2019 American Society for Microbiology | Privacy Policy | Website feedback

Print ISSN: 0066-4804; Online ISSN: 1098-6596